Acasă › Cancer pulmonar › Oregon › Portland
Studii clinice pentru Cancer pulmonar în Portland, OR
26 studii pentru Cancer pulmonar caută participanți în și în jurul orașului Portland (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
În curs de recrutareFaza 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
În curs de recrutareFaza 1/2
- Oregon Health & Science University (OHSU), Portland
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · La 12 mi distanță
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
În curs de recrutareFaza 1/2
- Providence Portland Medical Center ( Site 0043), Portland
- Providence Oncology and Hematology Care Clinic - Westside ( Site 0059), Portland
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
În curs de recrutareFaza 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
În curs de recrutareFaza 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
A Study of PHN-012 in Patients With Advanced Solid Tumors
În curs de recrutareFaza 1
- PHN-012-001 Site, Portland
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
În curs de recrutareFaza 3
- Oregon Health and Science University ( Site 0052), Portland
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
În curs de recrutareFaza 3
- Northwest Cancer Specialists, P.C., Portland
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
În curs de recrutareFaza 1/2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
În curs de recrutareFaza 2/3
- Providence Portland Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
În curs de recrutareFaza 2/3
- Providence Cancer Institute Franz Clinic, Portland
- Providence St. Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
În curs de recrutareFaza 1
- Providence Portland Medical Center, Portland
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
În curs de recrutareFaza 3
- Oregon Health and Science University, Portland
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
În curs de recrutareFaza 3
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
În curs de recrutareFaza 3
- Legacy Good Samaritan Hospital and Medical Center, Portland
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
În curs de recrutareFaza 1/2
- Providence Portland Medical Center, Portland
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
În curs de recrutareFaza 2
- Oregon Health and Science University, Portland
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
În curs de recrutareFaza 4
- OHSU Knight Cancer Institute, Portland
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
În curs de recrutareFaza 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- și încă 2
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
În curs de recrutareFaza 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- și încă 2
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
În curs de recrutareFaza 2/3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- și încă 1
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
- Oregon Health Sciences University, Portland
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
În curs de recrutareStudiu observațional
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · La 12 mi distanță
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
În curs de recrutareStudiu observațional
- Massive Bio SYNERGY-AI site, Portland
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
În curs de recrutareStudiu observațional
- Oregon Health & Science University, Portland
Studii pentru Cancer pulmonar în alte orașe
- Houston, TX78 studii
- Boston, MA62 studii
- New York City, NY60 studii
- Los Angeles, CA45 studii
- Washington, DC41 studii
- Arlington, VA41 studii
- Chicago, IL41 studii
- Nashville, TN40 studii
- Baltimore, MD40 studii
- St. Louis, MO39 studii
- Columbus, OH37 studii
- Philadelphia, PA36 studii
Alte studii în Portland
- Cancer pulmonar cu celule non-pătrate46 studii
- Cancer (toate tipurile)34 studii
- Cancer de prostată33 studii
- Cancer de sân33 studii
- Cancer metastatic29 studii
- Cancer colorectal28 studii
- Cancer ovarian27 studii
- Leucemie mieloasă acută25 studii
- Cancer endometrial24 studii
- Carcinom cu celule scuamoase de cap și gât19 studii
- Cancer pancreatic19 studii
- Insuficiență cardiacă17 studii
Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.